Quantum Leap Healthcare Collaborative

Recent papers from Quantum Leap Healthcare Collaborative

1. Cyclosporine treatment of ARDS due to severe COVID-19: The I-SPY COVID Adaptive Platform TrialAnnals of the American Thoracic Society · 2026
2. Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast CancerJAMA Oncology · 2026
3. Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 TrialAnnals of Surgical Oncology · 2026
4. Developing early endpoints in neoadjuvant breast cancer to support accelerated approval.Journal of Clinical Oncology · 2026
5. Neoadjuvant DAN-222 plus niraparib in high-risk HER2-negative breast cancer: Results from the I-SPY 2 adaptive platform trial.Journal of Clinical Oncology · 2026
6. C105-07 Dipeptidyl Peptidase 3 Predicts Mortality and Respiratory Support in a Multicenter Acute Hypoxemic Respiratory Failure CohortAmerican Journal of Respiratory and Critical Care Medicine · 2026
7. Abstract 2994: Integrative pathway analysis of I-SPY2 HER2+ breast cancers reveals drug-repurposing opportunitiesCancer Research · 2026
8. Abstract PS4-09-08: Expanding Diversity through Innovation: Development of the I-SPY ACCESS Initiative for the I-SPY2.2 and DCIS RECAST Clinical TrialsClinical Cancer Research · 2026
9. Abstract PS3-03-08: Initial results from RECAST DCIS: Multicenter platform trial testing active surveillance and novel endocrine therapy agents for DCIS managementClinical Cancer Research · 2026
10. Abstract PS3-11-10: Neoadjuvant HSP90 inhibition with ganetespib significantly improves distant relapse-free survival in I-SPY2 patients with HER2-negative breast cancer with low expression of immune genes and no DNA repair deficiencyClinical Cancer Research · 2026
11. Abstract PD6-09: Quantifying the Contribution of Doxorubicin and Cyclophosphamide (AC) to Pathologic Response Following Neoadjuvant Taxane Therapy: Analysis of the I-SPY2 TRIALClinical Cancer Research · 2026
12. Abstract PS1-01-05: Pneumonitis but not other immune related adverse events (irAEs) associate with pre-treatment immune signatures in early-stage breast cancer patients receiving neoadjuvant immunotherapy (IO): results from 5 IO arms in I-SPY2Clinical Cancer Research · 2026
13. PS4-05-28: Impact of Neoadjuvant Endocrine Therapy on MammaPrint Index in Hormone Receptor-Positive, HER2-Negative MammaPrint Low Risk Early-Stage Breast CancerClinical Cancer Research · 2026
14. Abstract PS5-01-24: Evorpacept (ALX-148) combined with trastuzumab deruxtecan in patients with HER2 positive/HER2low metastatic breast cancer (mBC): results from the PRE-ISPY phase Ib trialClinical Cancer Research · 2026
15. Abstract PS5-12-19: Pre-ispy trial: a phase i/ib oncology platform program (pre-i-spy-p1) nct05868226Clinical Cancer Research · 2026
16. Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trialClinical Cancer Research · 2026
17. Abstract PS4-02-01: Differential early response to neoadjuvant endocrine therapy in lobular versus non-lobular breast cancer on the Endocrine Optimization Pilot (EOP) of the I-SPY2 TrialClinical Cancer Research · 2026
18. RISE UP for breast cancer 2024: conference highlights & takeawaysBreast Cancer Research and Treatment · 2026
19. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerCell Reports Medicine · 2024
20. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapyBreast Cancer Research and Treatment · 2024